FUNDING
Company Profile
PureTech Health is a publicly traded biopharmaceutical company that discovers, develops, and commercializes breakthrough medicines by founding and funding a network of subsidiary companies, including Celea Therapeutics.
Founded 2005Boston, MassachusettsPRTC
Compare with
vs Tenon Medicalvs Jupiter Neurosciencesvs Ollin Biosciencesvs Assort Healthvs Triveni Biovs Scribe Therapeuticsvs Celea Therapeuticsvs OneMedNetvs Encore Medicalvs Flare Therapeuticsvs AEON Biopharmavs Apnimedvs Shionogivs Sanofivs Drug Farmvs Attovia Therapeuticsvs Chai Discoveryvs Colossal Biosciences
PureTech FAQ
- Is PureTech publicly traded?
- Yes. PureTech trades under the ticker PRTC.
Coverage Timeline
newest firstAll Coverage
FUNDING$180M Series B
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.
FUNDING
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
FUNDING$180 million
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.